Evidence map›Paper›PMID 40964012›Full record

ArticleResearch square2025

Assessment of a new class of slow γ-aminobutyric acid type A receptor anesthetic on mouse neuronal and astrocyte mitochondrial function.

Creed M Stary, Brian Griffiths, Xiaoyun Sun, Frances Davies, Alam Jahangir, Elizabeth Manis, Isabella Russo, Claire Ai Jue Dean, Lillen Montague, Edward Bertaccini

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Creed M StaryStanford University School of Medicine.
Brian GriffithsStanford University School of Medicine.
Xiaoyun SunStanford University School of Medicine.
Frances DaviesVA Palo Alto Health Care System.
Alam JahangirVA Palo Alto Health Care System.
Elizabeth ManisStanford University School of Medicine.
Isabella RussoStanford University School of Medicine.
Claire Ai Jue DeanStanford University School of Medicine.
Lillen MontagueStanford University School of Medicine.
Edward BertacciniVA Palo Alto Health Care System.

Funding

Non-coding RNA regulation of sex differences in strokeR01NS107445 · NINDS · STANFORD UNIVERSITY · PI STARY, CREED MICHAEL · 2019 to 2023
$1.8M
NINDS NIH HHS R01 NS107445
6 · The paper itself

Abstract

Our previous work has demonstrated efficacy of a new chemical class of the slow γ-aminobutyric acid type A receptor anesthetics that produce minimal effects on breathing and hemodynamics in rats. To advance pre-clinical testing, we screened one member of our class of compounds, KSEB 14 - 01, for mitochondrial toxicity in primary neuronal and astrocyte cultures from mice. Prior to treatment, cell cultures were incubated with: Mitotracker GreenTM to assess mitochondrial density, tetramethylrhodamine ethyl ester to assess mitochondrial membrane potential, dihydroethidium to assess reactive oxygen species (ROS), and 4',6-diamidino-2-phenylindole for cell counting. Cultures were treated with either propofol or KSEB 14 - 01 (dissolved in dimethylsulfoxide) at concentrations of 5, 10, or 30μM. ROS and mitochondrial membrane potential were measured for 6h after which mitochondrial density and cell proliferation were quantified. In parallel experiments, continuous oxygen consumption rates (OCR) were measured during glucose deprivation (GD) in astrocyte cultures. No significant differences were observed in cell count or between treatments. In both neurons and astrocytes, mitochondrial membrane potential was decreased at 6h with 5μM propofol and KSEB 14 - 01 treatment, but remained stable with higher doses of propofol and KSEB 14 - 01. Neuronal ROS generation increased in all groups by 6h but was significantly lower with 10 and 30μM propofol and KSEB 14 - 01. In all treatment groups, astrocyte ROS generation was significantly increased after 6h, with no differences between groups. After 48h GD astrocyte OCR was maintained with all doses of KSEB 14 - 01 and with the highest dose of propofol. In conclusion, this study demonstrates that KSEB 14 - 01 does not exhibit any overt mitochondrial toxicity relative to propofol in either neurons or astrocytes. Future in vivo work is warranted to explore the mechanisms and applications for maintenance of bioenergetic equivalents during cell stress with KSEB 14 - 01.

Indexed as

bioenergeticsbrainGABAGABAARmitochondrial membrane potentialoxidative phosphorylationoxygen consumptionreactive oxygen species

Identifiers

PMID40964012
PMCPMC12440076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.